XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Convertible Preferred Stock
Series B Non-Voting
Convertible Preferred Stock
Series A
Convertible Preferred Stock
Series A Non-Voting
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Total
Balance at Feb. 06, 2024 $ 3 $ (2)   $ 1
Balance (in Shares) at Feb. 06, 2024     3,197,975        
Issuance of common stock $ 2 (2)  
Issuance of common stock (in Shares)       2,207,553        
Issuance of Series A convertible preferred stock, net of issuance costs of $69 $ 2,931  
Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)   20,000,000            
Stock-based compensation expense 17   17
Net loss   (7,077) (7,077)
Balance at Mar. 31, 2024 $ 2,931 $ 5 13   (7,077) (7,059)
Balance (in Shares) at Mar. 31, 2024   20,000,000   5,405,528        
Stock-based compensation expense 321   321
Net loss   (22,243) (22,243)
Balance at Jun. 30, 2024 $ 2,931 $ 5 334   (29,320) (28,981)
Balance (in Shares) at Jun. 30, 2024   20,000,000   5,405,528        
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization $ 2,931 $ (2,931)   2,931
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares) 137,138 (20,000,000)            
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization $ 3 26,445   26,448
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)       2,722,207        
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, $ 20 248,437   248,457
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)       20,061,932        
Issuance costs of Pre-Closing Financing and reverse recapitalization (20,480)   (20,480)
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization $ 1 4,999   5,000
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)       1,208,883        
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing $ 56,097 $ 6 144,433   144,439
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing (in Shares)     2,439 5,600,000        
Issuance cost of the 2024 PIPE Financing $ (3,256) (8,573)   (8,573)
Stock-based compensation expense 1,750   1,750
Net loss   (28,623) (28,623)
Balance at Sep. 30, 2024 $ 2,931 $ 52,841 $ 35 397,345   (57,943) 342,368
Balance (in Shares) at Sep. 30, 2024 137,138 2,439 34,998,550        
Balance at Dec. 31, 2024 $ 2,931     $ 37 463,018 $ (41) (83,724) 382,221
Balance (in Shares) at Dec. 31, 2024 137,138     37,440,510        
Stock-based compensation expense     3,468 3,468
Net change in unrealized gains (losses) on marketable securities     35 35
Net loss     (20,999) (20,999)
Balance at Mar. 31, 2025 $ 2,931     $ 37 466,486 (6) (104,723) 364,725
Balance (in Shares) at Mar. 31, 2025 137,138     37,440,510        
Balance at Dec. 31, 2024 $ 2,931     $ 37 463,018 (41) (83,724) 382,221
Balance (in Shares) at Dec. 31, 2024 137,138     37,440,510        
Balance at Sep. 30, 2025 $ 2,931     $ 48 643,201 185 (159,574) 486,791
Balance (in Shares) at Sep. 30, 2025 137,138     48,384,150        
Balance at Mar. 31, 2025 $ 2,931     $ 37 466,486 (6) (104,723) 364,725
Balance (in Shares) at Mar. 31, 2025 137,138     37,440,510        
Issuance of common stock under employee stock purchase plan     109 109
Issuance of common stock under employee stock purchase plan (in Shares)       10,235        
Stock-based compensation expense     3,403 3,403
Net change in unrealized gains (losses) on marketable securities     (21) (21)
Net loss     (24,574) (24,574)
Balance at Jun. 30, 2025 $ 2,931     $ 37 469,998 (27) (129,297) 343,642
Balance (in Shares) at Jun. 30, 2025 137,138     37,450,745        
Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing     $ 11 179,989 180,000
Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing (in Shares)       10,933,405        
Issuance cost of the 2025 PIPE Financing     (10,356) (10,356)
Stock-based compensation expense     3,570 3,570
Net change in unrealized gains (losses) on marketable securities     212 212
Net loss     (30,277) (30,277)
Balance at Sep. 30, 2025 $ 2,931     $ 48 $ 643,201 $ 185 $ (159,574) $ 486,791
Balance (in Shares) at Sep. 30, 2025 137,138     48,384,150